Showing papers by "Stephen S Lim published in 2001"
TL;DR: It is demonstrated that combined AngII and ET receptor blockade has beneficial effects on myocardial fibrogenesis over individual treatments during adverse cardiac remodeling early post-MI.
41 citations
TL;DR: To analyse how well Pharmaceutical Benefits Scheme criteria for prescribing lipid‐lowering therapy identify people most at risk of coronary heart disease, and to determine the cost‐effectiveness of primary prevention therapy with pravastatin according to these criteria in Australia.
Abstract: Objectives: (i) To analyse how well Pharmaceutical Benefits Scheme (PBS) criteria for prescribing lipid-lowering therapy identify people most at risk of coronary heart disease (CHD); and (ii) to determine the cost-effectiveness of primary prevention therapy with pravastatin according to these criteria in Australia. Design: (i) Analysis of targeting of CHD risk according to PBS criteria; (ii) cost-effectiveness analysis for pravastatin as primary preventive therapy (40 mg/day), with a 20-year projection from 1999.
20 citations